The Technical Directors will support BioPharmaSpec’s growing structural and physicochemical characterization business
Jersey, UK and Malvern, PA. USA, October 25, 2016 BioPharmaSpec, a leading contract research organization (CRO) providing a full range of characterization services for the biotechnology industry, today announced it welcomes Dr. Richard Easton as Technical Director- Structural Analysis and Dr. Mark Millichip as Technical Director- Physicochemical Analysis. The senior appointments follow a period of significant growth for BioPharmaSpec and will allow clients to draw upon Dr. Easton’s and Dr. Millichip’s technical expertise and relevant experience when discussing their characterization requirements.
Dr. Richard Easton, previously Principal Scientist at SGS M-Scan, has considerable experience in the structural analysis of proteins and carbohydrates. He will be providing global technical support to the BioPharmaSpec Business Development team, while also having a key operational role in BioPharmaSpec laboratories in both the UK and the USA.
I am very excited to be joining BioPharmaSpec, a progressive and developing company with a firm foundation in the key aspects and techniques of analytical chemistry, that provide such vital information when determining glycoprotein structure
, said Dr. Easton. I look forward to sharing my specific technical knowledge with clients to aid them in designing cost-effective and efficient characterization strategies that will accelerate the development of their products.
Dr. Mark Millichip, previously Head of GMP Analytics at Sandoz and working to deliver on the company’s biosimilar pipeline, is highly experienced in the biophysical analysis of biopharmaceuticals. Dr. Millichip will also be providing global Business Development support, while expanding the in-house physicochemical capabilities at BioPharmaSpec.
This is a fast-paced and exciting time for BioPharmaSpec, as we expand both our client base and service offering
, said Dr. Millichip. I look forward to becoming part of the team and using my recent experience of large pharma biosimilar development to provide clients with a clearer understanding of the types of analyses and documentation necessary to meet the stringent requirements of the European and US regulators.
Speaking about the appointments, BioPharmaSpec CEO and MD Dr. Andrew J Reason said, BioPharmaSpec has become a highly regarded company in the CRO arena thanks to the drive and scientific expertise of our founders, the excellent calibre of our staff and the high quality of the science we produce. As more companies select BioPharmaSpec as their CRO of choice, we remain committed to strengthening our team and service provision to meet their requirements.